DEprescribing: Perceptions of PAtients Living With Advanced Cancer

Recruiting

• Conditions: Palliative Care; Deprescribing; Oncology
• Interventions: Other: Semi-directed individual interviews; Other: The self-administered questionnaires, rPATD and BMQ; Other: The self-administered FCCHL (Functional, Communicative and Critical Health Literacy) / HLS14 (14-item health literacy scale)

• Registration Number: NCT06193083
• Lead Sponsor: Nantes University Hospital

Brief Summary

Polymedication in palliative oncology care is a real public health problem. This phenomenon has been shown to increase the risk of iatrogenesis, reduce patients' quality of life and increase healthcare costs. For many years, health policies have been developed in geriatrics to reduce polymedication through deprescription tools.

Recently, palliative care initiatives have been introduced, but without having studied the potential specificities of this population (younger, with a different care dynamic and life trajectory). It is important to better understand this population's perceptions of deprescribing in order to adapt tools/actions to make these approaches more efficient.

The primary aim of this study is to investigate patients' perceptions of deprescribing in palliative cancer care, and the secondary aim is to investigate factors that may influence patients' attitudes and beliefs about deprescribing. At the same time, we will study the psychometric properties of the rPATD (Revised Patients' Attitudes Towards Deprescribing) in this population (a standardized questionnaire validated in geriatric medicine to assess patients' perceptions of deprescription).An ancillary study will be carried out to investigate the link between patients' health literacy and their perception of deprescribing (health literacy is defined as the ability to acquire, understand and use information in ways that promote and maintain good health).

To meet our objectives, we will conduct a 3-year national, prospective, observational, multicenter study with an exploratory sequential mixed design. The study will comprise an initial qualitative phase. Semi-directed individual interviews using a descriptive approach will be carried out (around 25 patients, over an 8-month period). Following analysis of the qualitative data, we will then carry out a quantitative study to determine the distribution of the different profiles within this population and the factors influencing the perception of deprescription. The self-administered questionnaires, rPATD and BMQ (medication beliefs questionnaire), potentially supplemented by other items following analysis of the qualitative data, will be administered to 300 patients (over a 12-month period).The ancillary study will be carried out during this second phase, using a validated self-questionnaire to assess patients' level of literacy.

Thanks to the different results, we will improve our knowledge of the perception of deprescription in palliative oncology care, in order to develop approaches adapted to the specificities of our population to reduce polymedication and thus improve the quality of life of our patients and reduce the risks of iatrogenia.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-12-21
• Study First Submitted QC: 2024-01-04
• Study First Posted: 2024-01-05
• Study Start: 2024-02-28
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-11
• Last Update Posted: 2024-04-12
• Primary Completion: 2025-02-28
• Study Completion: 2026-12-29

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 325

Inclusion Criteria

• Patient over 18 years of age
• Locally advanced or metastatic solid cancer (i.e., palliative care as defined by the World Health Organization)
• Life expectancy estimated by the physician at inclusion of less than 1 year (use of surprise question to help clinician estimate life expectancy)
• Hospitalized or in consultation
• With at least one PIMs (identified using STOPPfrail 2)
• Patient not having expressed opposition to participating in the study after receiving information from the physician.

For qualitative study patients :

• Patients who have signed an authorization for the recording of their voice during the semi-structured interview for the purpose of written transcription.

Exclusion Criteria

• Minor
• Major under guardianship, protected person
• Patient unable to speak or write French
• Patient with impaired judgment, cognitive or sensory impairment that prevents him/her from receiving informed information, answering questionnaires or participating in a study interview.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Qualitative study	Semi-directed individual interviews	The study will comprise an initial qualitative phase. Semi-directed individual interviews using a descriptive approach will be carried out (around 25 patients, over an 8-month period).
Quantitative study	The self-administered FCCHL (Functional, Communicative and Critical Health Literacy) / HLS14 (14-item health literacy scale)	Following analysis of the qualitative data, we will then carry out a quantitative study to determine the distribution of the different profiles within this population and the factors influencing the perception of deprescription. The self-administered questionnaires, rPATD and BMQ (medication beliefs questionnaire), potentially supplemented by other items following analysis of the qualitative data, will be administered to 300 patients (over a 12-month period). The ancillary study will be carried out during this second phase, using a validated self-questionnaire to assess patients' level of literacy.
Quantitative study	The self-administered questionnaires, rPATD and BMQ	Following analysis of the qualitative data, we will then carry out a quantitative study to determine the distribution of the different profiles within this population and the factors influencing the perception of deprescription. The self-administered questionnaires, rPATD and BMQ (medication beliefs questionnaire), potentially supplemented by other items following analysis of the qualitative data, will be administered to 300 patients (over a 12-month period). The ancillary study will be carried out during this second phase, using a validated self-questionnaire to assess patients' level of literacy.

Primary Outcome Measures

Name	Time	Method
To study patients' perceptions of deprescribing in palliative cancer care.	at study inclusion	To describe, understand and explain patients' attitudes and beliefs concerning deprescribing by means of individual semi-structured interviews (descriptive approach methodology with reflexive thematic analysis) and secondly using the rPATD questionnaire (questionnaire for assessing patients' perceptions of their treatments and deprescribing), which can be adapted following analysis of qualitative data.; rPATD: The rPATD is a questionnaire validated and adapted in French to assess patients' perceptions of their treatments and deprescribing.; This self-administered questionnaire consists of 22 questions rated on a 5-point Likert scale

Secondary Outcome Measures

Name	Time	Method
To investigate factors that may influence patients' attitudes and beliefs regarding de-prescribing.	at study inclusion	Influence of gender, age, level of education, type of cancer, number of metastatic sites, Performans status score, presence of systemic cancer treatment (chemotherapy, targeted therapy, immunotherapy, hormonal therapy, etc.), follow-up by a palliative care team, and other factors. ), follow-up by a palliative care team, patient's place of care, persons in charge of treatment, number of medications, number of potentially inappropriate medications (PIMs), prognosis assessed by the referring physician, patient's level of education and beliefs about treatments in general (BMQ questionnaire) on scores from the rPATD questionnaire.
To evaluate the psychometric properties of the rPATD in this population.	at study inclusion	Description of rPATD validation data in our population: validation of questionnaire structure, measurement of score reliability, concurrent validation with the BMQ questionnaire.; BMQ French version of the BMQ self-questionnaire, which studies patients' perceptions of medication .; A 5-point Likert-type scale was used for each item. The higher the sum of the scores obtained, the stronger the subject's belief.

Trial Locations

Locations (4)

CHD Vendée; 🇫🇷 La Roche-sur-Yon, France

Institut de Cancérologie de l'Ouest; 🇫🇷 Saint-Herblain, France

CHU de Nantes; 🇫🇷 Nantes, France

CH ST Nazaire; 🇫🇷 Saint-Nazaire, France